Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties
Physical Function Fatigue, weakness, altered body composition, reduced exercise recovery, headaches or chronic pain
M nm, i mi, tn nhang
But they cannot address the movement dysfunction, muscle weakness, compensatory patterns, and proprioceptive deficits that develop alongside shoulder injuries
ACMSD inhibition has been found to protect against acute kidney injury and NAFLD by increasing NAD + levels in a tissue-specific manner